EUVIMEDEUVIMED entdecken
Vergleichsstudie

Fluoroquinolone Susceptibility and Comparative Outcomes of Gram-negative Bloodstream Infection in Pediatric Patients With Hematologic Malignancy

Eleana Vasileiadi iD, Caitlin W Elgarten, Kelly D Getz, Richard Aplenc, Brian T Fisher iD

Journal of the Pediatric Infectious Diseases Society · 2025

DOI: 10.1093/jpids/piaf091 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of the Pediatric Infectious Diseases Society, 2025. Verfasst von Eleana Vasileiadi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Disease, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, United States. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Gram-Negative Bacterial Infections, Fluoroquinolones, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bacterial bloodstream infections (BSIs) cause morbidity and mortality in children with chemotherapy-associated neutropenia. While levofloxacin prophylaxis reduces BSI incidence, breakthrough infections occur in ~20%, often with fluoroquinolone non-susceptible (FQN-NS) gram-negative (GN) pathogens. The impact of FQN-NS on outcomes of GN BSI remains unknown. This study compares outcomes in pediatric patients with hematologic malignancies following FQN-NS vs. fluoroquinolone-susceptible (FQN-S) GN BSI.

Methods

A single-center cohort of pediatric patients with hematologic malignancies and neutropenia-associated GN BSI between 2014 and 2023 was retrospectively collected. The exposure was dichotomized as FQN-NS vs. FQN-S. Primary outcomes were intensive care unit admission and 30-day all-cause mortality, assessed from the day before to 30 days after blood culture collection. Modified Poisson regression with inverse probability of treatment weighting (IPTW) was used to balance covariates including age, calendar year of diagnosis, time from malignancy onset, cumulative neutropenia, granulocyte colony-stimulating factor use, international status, relapse/refractory disease, and type of underlying hematologic malignancy. A subgroup analysis assessed effect modification by resistance to empiric therapy. Only 5 patients contributed multiple events; clustering adjustments were not made.

Results

Among 119 GN BSI events, 82 (68.9%) were FQN-S and 37 (31.1%) FQN-NS. In IPTW-adjusted analyses, FQN-NS BSI was associated with higher 30-day all-cause mortality (aRR: 2.62, 95% CI: 0.39-17.64) and sepsis-related mortality (aRR: 2.60, 95% CI: 0.16-41.65), although confidence intervals were wide and not statistically significant. In a subgroup restricted to patients who received effective empiric therapy, estimates further reverted toward the null.

Conclusions

Fluoroquinolone non-susceptible GN BSI during neutropenia after chemotherapy was associated with increased 30-day all-cause and sepsis-related mortality in pediatric patients with hematologic malignancies, although not statistically significant. Effect modification by empiric therapy may have contributed to this association, suggesting that FQN-NS itself may not directly drive poor outcomes, but its impact appears mediated through resistance to empiric therapy, which is associated with worse outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematologic NeoplasmsGram-Negative Bacterial InfectionsFluoroquinolonesAnti-Bacterial AgentsBacteremiaGram-Negative BacteriaHumansMaleFemaleChildRetrospective StudiesChild, PreschoolAdolescentNeutropeniaInfantDrug Resistance, BacterialTreatment OutcomeMicrobial Sensitivity Tests

Stichwörter der Autor:innen

clinical outcomesfluoroquinolone resistancegram-negative bloodstream infectionshematologic malignanciesimmunocompromised hosts

Substanzen

FluoroquinolonesAnti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Infectious Disease, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, United States.
  • Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, United States.
  • Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, United States.

ORCID-Profile: Eleana Vasileiadi, Brian T Fisher

Zitieren

APA

Vasileiadi, E., Elgarten, C. W., Getz, K. D., Aplenc, R., & Fisher, B. T. (2025). Fluoroquinolone Susceptibility and Comparative Outcomes of Gram-negative Bloodstream Infection in Pediatric Patients With Hematologic Malignancy. Journal of the Pediatric Infectious Diseases Society. https://doi.org/10.1093/jpids/piaf091

Vancouver

Vasileiadi E, Elgarten CW, Getz KD, Aplenc R, Fisher BT. Fluoroquinolone Susceptibility and Comparative Outcomes of Gram-negative Bloodstream Infection in Pediatric Patients With Hematologic Malignancy. Journal of the Pediatric Infectious Diseases Society. 2025. doi:10.1093/jpids/piaf091

BibTeX
@article{Vasileiadi2025,
  author = {Vasileiadi, Eleana and Elgarten, Caitlin W and Getz, Kelly D and Aplenc, Richard and Fisher, Brian T},
  title = {Fluoroquinolone Susceptibility and Comparative Outcomes of Gram-negative Bloodstream Infection in Pediatric Patients With Hematologic Malignancy},
  journal = {Journal of the Pediatric Infectious Diseases Society},
  year = {2025},
  doi = {10.1093/jpids/piaf091}
}
Kostenlos starten →